Intrexon Corporation (NYSE:XON) had its price objective upped by Stifel Nicolaus from $39.00 to $57.00 in a report released on Friday, November 10th, Marketbeat.com reports. Stifel Nicolaus currently has a buy rating on the biotechnology company’s stock.
A number of other equities analysts also recently issued reports on XON. Northland Securities set a $30.00 price objective on Intrexon Corporation and gave the stock a buy rating in a research report on Monday, August 7th. BidaskClub cut Intrexon Corporation from a hold rating to a sell rating in a research report on Friday, August 4th. Zacks Investment Research cut Intrexon Corporation from a hold rating to a sell rating in a research report on Thursday, July 13th. JMP Securities reissued an outperform rating and issued a $42.00 price objective on shares of Intrexon Corporation in a research report on Thursday, October 5th. Finally, Griffin Securities reissued a buy rating and issued a $55.00 price objective on shares of Intrexon Corporation in a research report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $38.50.
Intrexon Corporation (XON) opened at $13.34 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.05 and a debt-to-equity ratio of 0.01. Intrexon Corporation has a 1 year low of $10.26 and a 1 year high of $31.68.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by BBNS and is owned by of BBNS. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://baseballnewssource.com/markets/stifel-nicolaus-raises-intrexon-corporation-xon-price-target-to-57-00/1774417.html.
Hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC boosted its stake in Intrexon Corporation by 2,031.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 4,937 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in shares of Intrexon Corporation in the third quarter worth $121,000. Federated Investors Inc. PA acquired a new stake in shares of Intrexon Corporation in the second quarter worth $172,000. SG Americas Securities LLC acquired a new stake in shares of Intrexon Corporation in the third quarter worth $139,000. Finally, Principal Financial Group Inc. purchased a new position in shares of Intrexon Corporation in the second quarter valued at $212,000. 77.17% of the stock is owned by institutional investors.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with our FREE daily email newsletter.